Global healthcare company Penumbra has introduced its new advanced Lightning Bolt7 arterial thrombectomy system.

In March this year, the company secured approval from the US Food and Drug Administration for the system and is claimed to be the most advanced product of its kind in the market.

Lightning Bolt 7 introduces a new method called modulated aspiration to remove blood clots.

This method combines the company’s Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm.

Lightning Bolt 7 helps enhance the capability to eliminate sizable fibrous blood clots rapidly and effectively from arteries, while minimising blood loss.

The advanced solution effectively addresses conditions such as hibernating thrombus, visceral occlusions and acute limb ischemia (ALI).

Penumbra chief medical officer Dr James Benenati said: “With our latest advancements in computer-aided technologies, Penumbra offers one of the most comprehensive mechanical thrombectomy product lines for arterial, venous, pulmonary and mesenteric thrombus.

“Lightning Flash and Lightning Bolt 7 will continue to advance the standard of care for these difficult conditions, removing clot from the body quickly, safely, in a single session and without the need for lytics or open surgery, potentially improving quality of life for our patients.”

Part of Penumbra’s Indigo System with Lightning portfolio, Lightning Bolt 7 leverages the Penumbra ENGINE to distinguish between blood clot and blood flow.

Furthermore, the system facilitates the identification of friction occurring within the catheter and coordinates the rapid opening and closing of the valves to overcome any resistance between the catheter tip and the clot.

This enhances the vacuum force at the catheter tip, enabling quick and effective removal of blood clots.

Penumbra’s arterial catheters, which feature MaxID hypotube technology, can integrate with Lightning Bolt 7.